---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-041085"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:26:27.861288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nektar Q1 net loss $50.9M, cash $220.7M; Phase 2 data expected June

## Summary
- Cash & marketable securities $220.7M, expected to fund operations into Q4 2026.
- Revenue $10.5M, down from $21.6M YoY due to sale of Huntsville facility.
- Net loss $50.9M ($0.24/share) vs $36.8M ($0.19) in Q1 2024; non-GAAP loss $46.4M.
- Topline Phase 2 data for rezpegaldesleukin in atopic dermatitis expected June 2025.
- FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis.

## SEC filing metadata
- accession: 0001213900-25-041085
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025041085/0001213900-25-041085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025041085/ea0241353-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-041085
- JSON: https://secwatch.observer/filing/0001213900-25-041085.json
- Plain text: https://secwatch.observer/filing/0001213900-25-041085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.